Transgene starts trials of ‘digital’ cancer vaccine with NECUndeterred by two clinical failures for its cancer immunotherapies in 2019, Transgene has kicked off the New Year Share XTransgene starts trials of ‘digital’ cancer vaccine with NEChttps://pharmaphorum.com/news/transgene-starts-trials-of-digital-cancer-vaccine-with-nec/
Sillajen explains Pexa-Vec trial failure – it was the rescue medsSouth Korean biotech Sillajen was hit hard last week when its oncolytic virus therapy Pexa-Vec failed a phase Share XSillajen explains Pexa-Vec trial failure – it was the rescue medshttps://pharmaphorum.com/news/sillajen-explains-pexa-vec-trial-failure-it-was-the-rescue-meds/
Transgene begins trials of head and neck cancer vaccineVirus-based immunotherapy biotech Transgene is to begin clinical trials of its head and neck cancer drug candidate TG4050 Share XTransgene begins trials of head and neck cancer vaccinehttps://pharmaphorum.com/news/transgene-begins-trials-of-head-and-neck-cancer-vaccine/
